632352-88-6

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[[(4-nitrophenoxy)carbonyl]amino]-, 1,1-dimethylethyl ester
• CAS NO: 632352-88-6
• Molecular Formula: C17H23N3O6
• Molecular Weight: 365.386
• Mol File: 632352-88-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[[(4-nitrophenoxy)carbonyl]amino]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[[(4-nitrophenoxy)carbonyl]amino]-, 1,1-dimethylethyl ester(632352-88-6)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[[(4-nitrophenoxy)carbonyl]amino]-, 1,1-dimethylethyl ester(632352-88-6)

Safety Data

• Hazardous Substances Data: 632352-88-6(Hazardous Substances Data)

Upstream product

• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 7693-46-1 4-Nitrophenyl chloroformate 

Downstream Products

• 1056674-81-7 tert-butyl 4-(3-(4-phenoxyphenyl)ureido)-piperidine-1-carboxylate 
• 1056673-41-6 tert-butyl 4-(3-(4-(morpholinosulfonyl)phenyl)ureido)piperidine-1-carboxylate 
• 950184-31-3 4-(3-Cyclohexyl-ureido)-piperidine-1-carboxylic acid tert-butyl ester 
• 913548-29-5 1-(1-acetypiperidin-4-yl)-3-(adamantan-1-yl)urea 
• 696643-77-3 C₃₃H₄₅F₃N₄O₃ 

Relevant articles and documents

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

SOLUBLE EPOXIDE HYDROLASE INHIBITORS

Disclosed are urea compounds, stereoisomer, or pharmaceutical acceptable salt thereof, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases.

17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES

In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17?-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of